share_log

HC Wainwright & Co. Reiterates Buy on BioCryst Pharma, Maintains $30 Price Target

HC Wainwright & Co. Reiterates Buy on BioCryst Pharma, Maintains $30 Price Target

HC Wainwright & Co.重申买入 BioCryst Pharma,维持30美元的目标股价
Benzinga ·  2023/08/04 06:14

HC Wainwright & Co. analyst Andrew Fein reiterates BioCryst Pharma (NASDAQ:BCRX) with a Buy and maintains $30 price target.

HC Wainwright & Co. 分析师安德鲁·费恩重申了BioCryst Pharma(纳斯达克股票代码:BCRX)的买入,并维持30美元的目标股价。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发